MX2020007268A - Regimen de dosificacion de siponimod. - Google Patents

Regimen de dosificacion de siponimod.

Info

Publication number
MX2020007268A
MX2020007268A MX2020007268A MX2020007268A MX2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A MX 2020007268 A MX2020007268 A MX 2020007268A
Authority
MX
Mexico
Prior art keywords
siponimod
dosing regimen
stroke
ischemic stroke
crystals
Prior art date
Application number
MX2020007268A
Other languages
English (en)
Inventor
Eric Legangneux
Anne Gardin
Erik Wallström
Jang- Ho Cha
Iii Carl Joseph Malanga
Kasra Shakeri-Nejad
Christian Wolf
Frank Dahlke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020007268A publication Critical patent/MX2020007268A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un nuevo régimen de dosificación para la administración de siponimod o cocristales o sales farmacéuticamente aceptables del mismo, en el tratamiento del accidente cerebrovascular, en particular un accidente cerebrovascular isquémico, por ejemplo, un accidente cerebrovascular isquémico agudo.
MX2020007268A 2017-09-29 2018-09-27 Regimen de dosificacion de siponimod. MX2020007268A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565261P 2017-09-29 2017-09-29
PCT/IB2018/057479 WO2019064212A1 (en) 2017-09-29 2018-09-27 DOSAGE DIAGRAM OF SIPONIMOD

Publications (1)

Publication Number Publication Date
MX2020007268A true MX2020007268A (es) 2020-08-17

Family

ID=63840891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007268A MX2020007268A (es) 2017-09-29 2018-09-27 Regimen de dosificacion de siponimod.

Country Status (11)

Country Link
US (1) US20200316021A1 (es)
EP (1) EP3687530A1 (es)
JP (1) JP2020535147A (es)
KR (1) KR20200062241A (es)
CN (1) CN111107845A (es)
AU (1) AU2018341154A1 (es)
CA (1) CA3073910A1 (es)
IL (1) IL273419A (es)
MX (1) MX2020007268A (es)
RU (1) RU2020114750A (es)
WO (1) WO2019064212A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020174408A1 (en) * 2019-02-27 2020-09-03 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
EP3972954A1 (en) * 2019-05-21 2022-03-30 Synthon B.V. Siponimod maleic acid and fumaric acid salt
WO2021214717A1 (en) * 2020-04-23 2021-10-28 Novartis Ag Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
WO2024126409A1 (en) * 2022-12-12 2024-06-20 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
PT2379497E (pt) 2008-12-18 2013-11-29 Novartis Ag Sal hemifumarato do ácido 1-(4-{1-[(e)-4-ciclo-hexil-3- trifluorometil-benziloxi-imino]-etil}-2-etil-benzil)- azetidina-3-carboxílico
CN103204794A (zh) 2008-12-18 2013-07-17 诺瓦提斯公司 新的盐
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
JP5657565B2 (ja) * 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
CA2823616C (en) 2011-01-07 2019-01-29 Novartis Ag Immunosuppressant formulations
EP2809645A1 (en) 2012-02-03 2014-12-10 Novartis AG Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
SI3129006T1 (sl) 2014-04-10 2021-08-31 Novartis Ag Formulacija imunosupresivov
SG11201607894RA (en) * 2014-04-10 2016-10-28 Novartis Ag S1p modulator immediate release dosage regimen
SG11201702483QA (en) * 2014-09-29 2017-04-27 Scripps Research Inst Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders

Also Published As

Publication number Publication date
CN111107845A (zh) 2020-05-05
US20200316021A1 (en) 2020-10-08
KR20200062241A (ko) 2020-06-03
AU2018341154A1 (en) 2020-03-12
CA3073910A1 (en) 2019-04-04
IL273419A (en) 2020-05-31
JP2020535147A (ja) 2020-12-03
WO2019064212A1 (en) 2019-04-04
EP3687530A1 (en) 2020-08-05
RU2020114750A (ru) 2021-10-29

Similar Documents

Publication Publication Date Title
MX2020007268A (es) Regimen de dosificacion de siponimod.
MY195681A (en) Aqueous Pharmaceutical Formulation Comprising Anti-Pd-L1 Antibody Avelumab
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
EP4219526A3 (en) Method for preparing amg 416
AR103680A1 (es) Inhibidores selectivos de bace1
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
PH12018500903A1 (en) Pyranodipyridine compound
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
EA201691741A1 (ru) Фармацевтическая композиция
TN2018000326A1 (en) Granule formulation for oral administration.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
IN2014MU00916A (es)
MX2020007326A (es) Regimen de dosificacion de siponimod.
MX357918B (es) Proceso para la obtencion de enantiomeros de pirlindol opticamente activos y sales de los mismos.
MD20180049A2 (ro) Compoziţie farmaceutică
TWD186752S (zh) 冷充填瓶
MX2020007270A (es) Formulacion parenteral que comprende siponimod.
EA201790526A1 (ru) Фармацевтические комбинации ситаглиптина
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
IN2013CH04314A (es)